Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04094025 · ClinicalTrials.gov registry record · Phase 1
Irritation and Sensitization Study of d-Amphetamine Transdermal System
A Phase 1 study, sponsored by Noven Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT04094025: Completed Phase 1 study, sponsored by Noven Therapeutics.
NCT04094025 is a Phase 1 study that has completed, run by Noven Therapeutics. The registered enrollment target is 229 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (282% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04094025, a Phase 1 study, has completed, sponsored by Noven Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
The study will assess skin irritation as well as sensitization for d-ATS patch in healthy subjects.
Primary Outcome
Number of participants with sensitization potential after repeated exposure to d-ATS, placebo and saline patches in healthy adults
Interventions
- DRUG dATS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2020-05-16 |
| Phase | Phase 1 |
What the finished NCT04094025 record still lists
NCT04094025 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (282% higher).
The record links to 0 conditions, and to 1 intervention - of which dATS is the first listed.
NCT04094025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04094025 about?
NCT04094025 is a clinical study titled "Irritation and Sensitization Study of d-Amphetamine Transdermal System". The study will assess skin irritation as well as sensitization for d-ATS patch in healthy subjects.
What is the current status of trial NCT04094025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2019-12-02. Estimated completion is 2020-05-16.
What interventions are being tested in trial NCT04094025?
The interventions under investigation include: dATS (DRUG).
Who is sponsoring clinical trial NCT04094025?
This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04094025's enrollment target sits among peer trials
229 221st of 2000 higher than 1,780 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI